however;
Among all subjects who received MultiStem treatment, 15.4% of patients achieved an Excellent Outcome, defined clinically as attaining mRS 0-1, NIHSS 0-1 and BI >=95, compared to 6.6% of patients that received placebo, (p=0.10);
As described in the table below, patients who received MultiStem treatment earlier in the treatment window (24-36 hours post-stroke) exhibited more favorable recovery on the primary and key secondary endpoints than patients who received placebo or patients who received MultiStem treatment later (e.g. Excellent Outcome, p = 0.03), and this treatment effect was even more pronounced the earlier the MultiStem administration within the 24-36 hour timeframe;
